Appellate board stays previous order that rescinded the patent on ceritinib in India, giving Novartis the upper hand for now. The spotlight is now on procedural aspects and additional evidence/submission by challenger Natco and rebuttal by the Swiss multinational.
The ceritinib patent case in India appears far from over, with an appellate authority now ordering a stay on a previous ruling that rescinded the patent on the lung cancer drug last year.
India’s Intellectual Property Appellate Board [IPAB] has now held that Novartis AG has made a “strong case” for securing...
Gefurulimab will give AstraZeneca a new option to compete against Argenx’s Vyvgart Hytrulo, which is available subcutaneously.
The Swiss giant has been talking to the US government about selling medicines directly to patients.
The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.
